CA3189818A1 - Methods and compositions for treating lung conditions - Google Patents

Methods and compositions for treating lung conditions

Info

Publication number
CA3189818A1
CA3189818A1 CA3189818A CA3189818A CA3189818A1 CA 3189818 A1 CA3189818 A1 CA 3189818A1 CA 3189818 A CA3189818 A CA 3189818A CA 3189818 A CA3189818 A CA 3189818A CA 3189818 A1 CA3189818 A1 CA 3189818A1
Authority
CA
Canada
Prior art keywords
mscs
exo
msc
ntfs
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189818A
Other languages
English (en)
French (fr)
Inventor
Chaim LEBOVITS
Revital ARICHA
Yossef Levy
Ralph Kern
Haggai KASPI
Jonathan SEMO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brainstorm Cell Therapeutics Ltd
Original Assignee
Brainstorm Cell Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brainstorm Cell Therapeutics Ltd filed Critical Brainstorm Cell Therapeutics Ltd
Publication of CA3189818A1 publication Critical patent/CA3189818A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3189818A 2020-07-20 2021-07-20 Methods and compositions for treating lung conditions Pending CA3189818A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053780P 2020-07-20 2020-07-20
US63/053,780 2020-07-20
US202163133350P 2021-01-03 2021-01-03
US63/133,350 2021-01-03
PCT/IL2021/050885 WO2022018729A1 (en) 2020-07-20 2021-07-20 Methods and compositions for treating lung conditions

Publications (1)

Publication Number Publication Date
CA3189818A1 true CA3189818A1 (en) 2022-01-27

Family

ID=77265158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189818A Pending CA3189818A1 (en) 2020-07-20 2021-07-20 Methods and compositions for treating lung conditions

Country Status (7)

Country Link
US (1) US20230310507A1 (https=)
EP (1) EP4181935A1 (https=)
JP (2) JP7691488B2 (https=)
AU (1) AU2021313472B2 (https=)
CA (1) CA3189818A1 (https=)
IL (1) IL299997A (https=)
WO (1) WO2022018729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
EP4252761A4 (en) * 2020-11-26 2024-06-05 Samsung Life Public Welfare Foundation COMPOSITION FOR THE TREATMENT OF INFECTIOUS DISEASES, COMPRISING EXOSOMES DERIVED FROM THROMBIN-PROCESSED STEM CELLS
KR20240003167A (ko) * 2022-06-30 2024-01-08 주식회사 지씨셀 편도유래줄기세포를 유효성분으로 포함하는 감염성 폐 질환의 예방 또는 치료용 조성물
WO2024236603A1 (en) * 2023-05-18 2024-11-21 Khorakiwala Zahabiya Growth factor concentrate composition
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2829586C (en) 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
DK2880151T3 (da) * 2012-08-06 2020-08-17 Brainstorm Cell Therapeutics Ltd Fremgangsmåder til frembringelse af mesenkymale stemceller, som udskiller neurotrofiske faktorer
ES2909752T3 (es) * 2013-08-01 2022-05-10 Swedish Stromabio Ab MSC en el tratamiento de enfermedades pulmonares inflamatorias
KR101843634B1 (ko) 2016-04-15 2018-03-30 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics
US12233092B2 (en) 2018-04-10 2025-02-25 Brainstorm Cell Therapeutics Ltd. MSC-NTF specific exosomes and use thereof
EP3813858B1 (en) * 2018-06-29 2023-11-01 North Carolina State University Therapeutic lung repair by inhalation of lung spheroid exosomes
BR112022017557A2 (pt) * 2020-03-05 2022-12-27 Mesoblast Int Sarl Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
WO2021181399A1 (en) * 2020-03-12 2021-09-16 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
CA3173216A1 (en) * 2020-04-03 2021-10-07 Silviu Itescu Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
EP4132479A1 (en) * 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof

Also Published As

Publication number Publication date
JP2023534524A (ja) 2023-08-09
AU2021313472A1 (en) 2023-02-23
JP2025128209A (ja) 2025-09-02
AU2021313472B2 (en) 2025-10-16
US20230310507A1 (en) 2023-10-05
WO2022018729A1 (en) 2022-01-27
JP7691488B2 (ja) 2025-06-11
EP4181935A1 (en) 2023-05-24
IL299997A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
AU2021313472B2 (en) Methods and compositions for treating lung conditions
US11759481B2 (en) Methods and compositions relating to exosomes
WO2021180237A1 (zh) 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
JP2023532752A (ja) タンパク質会合細胞外小胞の製造プロセス
WO2022022707A1 (zh) 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
Xu et al. Safety, efficacy and bio-distribution analysis of exosomes derived from human umbilical cord mesenchymal stem cells for effective treatment of bronchopulmonary dysplasia by intranasal administration in mice model
JP7821414B2 (ja) 呼吸器疾患治療のための幹細胞
CN116897887A (zh) 一种病毒性哮喘动物模型的构建方法
WO2021210026A1 (en) A cell-free growth factor concentrate, method of preparing the same and a kit thereof
Talukdar Human umbilical cord blood in emerging disease
Hassen et al. Studying the therapeutic effect of umbilical cord stem cell in pneumonia caused by covid-19
CN101947241A (zh) 用于保护血管内皮细胞氧化损伤的抗氧化制剂及其制备方法
Xu et al. Effect Analysis of Extracellular Vesicles in the Treatment of Bronchopulmonary Dysplasia via Different Drug Delivery and Administration Routes
Moawed et al. Assessment of cord blood vascular endothelial growth factor levels and circulating CD34+ cells in preterm infants with respiratory distress syndrome
Bignold et al. CXCL12 drives pericyte accumulation and airway remodeling in allergic airway disease
HK40089111A (zh) 结合蛋白质的细胞外囊泡的制造方法
Vergadi et al. A novel IL-10–DEL-1 axis promotes granulopoiesis and sepsis survival in early life
HK40082197A (en) Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof
CN101940592A (zh) 用于治疗缺血性脑血管疾病的制剂及其制备方法
Zhou et al. Feasibility and Safety of Autologous Cord Blood Derived Cell Administration in Extremely Preterm Infants (Cord-Safe Study)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240830

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241015

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250623

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250623

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251208

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260120